• Contact Us
  • FI
  • SE
FICAN West
  • Home
  • FicanWest
    • Personnel
    • Organization and strategy
    • Collaboration
    • Research and development projects
  • For patients
    • Care pathways
    • Access to treatment
    • Join a cancer trial
    • Support to patients
    • Wellness
    • Rehabilitation
    • Family and friends
    • The Cancer Centre’s Client Board
  • For professionals
    • GeneCa
    • Molecular Tumor Board
    • Care Instructions
    • Education
  • For researchers
    • Ongoing Clinical Trials
    • Research groups
    • For medical industry
  • News
  • Search
  • Menu
  • Home
  • FicanWest
    • Personnel
    • Organization and strategy
    • Collaboration
    • Research and development projects
  • For patients
    • Care pathways
    • Access to treatment
    • Join a cancer trial
    • Support to patients
    • Wellness
    • Rehabilitation
    • Family and friends
    • The Cancer Centre’s Client Board
  • For professionals
    • GeneCa
    • Molecular Tumor Board
    • Care Instructions
    • Education
  • For researchers
    • Ongoing Clinical Trials
    • Research groups
    • For medical industry
  • News

    Trials open for cancer patients

    Cancer treatment runs in parallel with advanced scientific research. FICAN West is the second largest cancer research center in Finland. Its mission is to coordinate cancer research and teaching in the entire West-coast area.

    We promote cancer research and the use of up-to-date scientific data within FICAN West and in the whole of Finland.

    The Turku Clinical Research Center provides services in the field of health scientific research for researchers of the University of Turku and the Turku special responsibility area.

    This takes you to the web page of the Turku Clinical Research centre

    Glossary

    Special terms are needed when clinical trials are discussed. Laaketutkimukset.fi-website (in Finnish) contains explanations of the most common terms used in clinical trials.

    STUDY CENTER AND PRINCIPAL INVESTIGATORSTUDY CODETITLE OF THE STUDY
    GYNECOLOGICAL CANCER
    TUCH / Sakari HietaneninnovaTV 301A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin vs Investigator’s Choice Chemotherapy in Second- or Third-Line Recurrent or Metastatic Cervical Cancer
    TUCH / Sakari HietanenKEYNOTE-B96 / ENGOT-ov65A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus
    Placebo in Combination With Paclitaxel With or Without Bevacizumab for the Treatment of Platinum-resistant Recurrent Ovarian Cancer
    TUCH / Sakari HietanenDOVACCA Randomized Clinical Trial Investigating Olaparib, Durvalumab (MEDI4736) and UV1 as Maintenance Therapy in BRCAwt Patients with Recurrent Ovarian Cancer
    LYMPHOMA
    TUCH / Sirkku JyrkkiöPOLAR BEARR-MINI-CHOP versus R-MINI-CHP in combination with polatuzumab-vedotin, as primary treatment for patients with diffuse large B-cell lymphoma, ≥80 years, or frail ≥75 years
    TYKS / Erika AlanneGENMAB-GCT3013-05A randomized, open-label, phase 3 trial of Epcoritamab vs Investigator’s choice chemotherapy in relapsed/refractory diffuse large B-cell lymphoma
    TYKS / Taina ReunamoInMindA Phase 3, Randomized, Double-Blind, Placebo-Controlled,
    Multicenter Study to Evaluate the Efficacy and Safety of
    Tafasitamab Plus Lenalidomide in Addition to Rituximab Versus
    Lenalidomide in Addition to Rituximab in Patients With
    Relapsed/Refractory (R/R) Follicular Lymphoma Grade 1 to 3a or
    R/R Marginal Zone Lymphoma
    BREAST CANCER
    Vaasa Central Hospital / Antti JekunenCO41101A Phase III, Double-blind, Placebo-controlled, Randomized Study Of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer
    TUCH / Riikka HuovinenZESTA RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY
    COMPARING THE EFFICACY AND SAFETY OF
    NIRAPARIB TO PLACEBO IN PARTICIPANTS WITH
    EITHER HER2-NEGATIVE BRCA-MUTATED OR
    TRIPLE-NEGATIVE BREAST CANCER WITH
    MOLECULAR DISEASE BASED ON PRESENCE OF
    CIRCULATING TUMOR DNA AFTER DEFINITIVE
    THERAPY (
    TUCH / Riikka HuovinenlidERAA PHASE III, RANDOMIZED, OPEN-LABEL,
    MULTICENTER STUDY EVALUATING THE
    EFFICACY AND SAFETY OF ADJUVANT
    GIREDESTRANT COMPARED WITH
    PHYSICIAN’S CHOICE OF ADJUVANT
    ENDOCRINE MONOTHERAPY IN PATIENTS
    WITH ESTROGEN RECEPTOR POSITIVE,
    HER2-NEGATIVE EARLY BREAST CANCER
    TUCH / Riikka HuovinenDESTINY – Breast12An Open-Label, Multinational, Multicenter, Phase 3b/4 Study of
    Trastuzumab Deruxtecan in Patients With or Without Baseline
    Brain Metastasis With Previously-Treated Advanced/Metastatic
    HER2-Positive Breast Cancer
    BLADDER CANCER
    TUCH / Peter BoströmFINNBLADDER 9Treatment of stage Ta cancer of the urinary bladder with a high risk of relapse – blue-light cystoscopy and optimized dosage of mitomycin-C.
    TUCH / Peter BoströmFINNBLADDER 10​Intravesical Instillation Therapy With Bacillus Calmette-Guérin (BCG) and Sequential BCG and Electromotive Mitomycin-C (EMDA-MCC) in Patients With High-risk Non-muscle-invasive Bladder Carcinoma.
    TUCH / Peter BoströmCA017-078A Phase 3, Randomized, Study of Neoadjuvant Chemotherapy Alone Versus Neoadjuvant Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Post- Surgery Therapy With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle- Invasive Bladder Cancer
    RENAL CANCER
    TUCH / Kalle MattilaMK-6482-022A Multicenter, Double-blind, Randomized Phase 3 Study to Compare the
    Efficacy and Safety of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma (ccRCC) Post Nephrectomy
    TUCH / Kalle MattilaMK6482-005An Open-label,Randomized Phase 3 Study of MK-6482 Versus Everolimus in participants with Advanced Renal Cell Carcinoma that has progressed after prior PD-1/L1 and VEGFR Tyrosine Kinase Inhibitor Therapy
    TUCH / Kalle MattilaMK6482-012An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety
    of Pembrolizumab in Combination with Belzutifan and Lenvatinib, or MK-1308A in Combination with Lenvatinib, versus Pembrolizumab and Lenvatinib, as First-line Treatment in Participants with Advanced Clear Cell Renal Cell Carcinoma
    TUCH / Kalle MattilaMK6482-011An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination
    with Lenvatinib (MK-7902) vs Cabozantinib for Second-line or Third-line Treatment in
    Participants with Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-
    PD-1/L1 Therapy
    PROSTATE CANCER
    TUCH / Peter BoströmSPCG-15Surgery or radiation therapy in the treatment of locally advanced prostate cancer – open, randomized clinical trial.
    TUCH / Peter Boström TALAPRO-3A PHASE 3, RANDOMIZED, DOUBLE-BLIND, STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER
    TUCH / Peter BoströmHIFU-PRO-BPHA early phase 1 non-randomized prospective single-institutional and four arm study to determine the applicability, feasibility and safety of MRI guided transurethral HIFU ablation of prostate separately in each pre-specified group/arm
    TUCH / Jukka KemppainenADTPSMA2The Effect of Androgen Deprivation Therapy on the Expression of Prostate Specific Membrane Antigen (PSMA) Evaluated With 18F-PSMA PET/CT in Treatment naïve Metastatic Prostate Cancer Patients
    TUCH / Otto EttalaESTO-2Impact of atorvastatin on prostate cancer progression after initiation of androgen deprivation therapy- lipid metabolism as a novel biomarker to predict prostate cancer progression – Phase 3, double-blind randomized clinical trials FinnProstata XV
    HEAD AND NECK CANCER
    HEMATOLOGICAL CANCER
    TUCH / Mervi PutkonenMagnetisMM-5Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
    TUCH / Mervi PutkonenMagnetisMM-7Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant
    TUCH / Mervi PutkonenExcaliber-RRMMOpen-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
    TUCH / Juha RantiCartitude-5A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy
    MELANOMA
    TUCH / Kalle MattilaRELATIVITY 098A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy with Relatlimab and Nivolumab Fixed-dose Combination versus Nivolumab Monotherapy after Complete Resection of Stage III-IV Melanoma
    GASTROINTESTINAL CANCER
    Satasairaala Hospital / Kalevi PulkkanenSSGXXIIThree Versus Five Years of Adjuvant Imatinib as Treatment of Patients With Operable GIST With a High Risk for Recurrence
    TUCH / Pirita VarpeRESETLaparotomy vs Laparoscopy vs Robotic vs TaTME Rectal Surgery Matched Parallel Cohort Trial for High Surgical Risk Cancer Patients, With Mid- to Low Rectal Cancer

    TUCH / Raija Ristamäki

    Vaasa Central Hospital / Pia Österlund

    BREAKWATERAN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE 3 STUDY OF FIRST-LINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS STANDARD OF CARE THERAPY WITH A SAFETY LEAD-IN OF ENCORAFENIB AND CETUXIMAB PLUS CHEMOTHERAPY IN PARTICIPANTS WITH METASTATIC BRAF V600E-MUTANT COLORECTAL CANCER
    TUCH / Raija RistamäkiKRYSTALA Randomized Phase 3 Study of MRTX849 in
    Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy
    HEPATOCELLULAR CARCINOMA
    TUCH / Eetu HeerväIMBrave251A PHASE III, OPEN-LABEL, RANDOMIZED STUDY
    OF ATEZOLIZUMAB WITH LENVATINIB OR
    SORAFENIB VERSUS LENVATINIB OR
    SORAFENIB ALONE IN HEPATOCELLULAR
    CARCINOMA PREVIOUSLY TREATED WITH
    ATEZOLIZUMAB AND BEVACIZUMAB
    LUNG CANCER
    TUCH / Maria Silvoniemi and Vaasa Central Hospital / Antti JekunenASTEROIDAblative STEreotactic RadiOtherapy wIth Durvalumab (MEDI4736). An Open Label Randomized Phase II Trial With Durvalumab Following Stereotactic Body Radiotherapy (SBRT) in Patients With Stage I Non-small Cell Lung Cancer (NSCLC)
    TUCH / Maria SilvoniemiDARTA study of Durvalumab, a type of immunotherapy, for treatment of patients with non-small cell lung cancer with positive or negative PD-L1 expression, following chemotherapy and radiotherapy
    TUCH / Maria SilvoniemiMK7684A-008A Phase 3, Randomized, Double-Blind Study of MK-7684A in Combination with Etoposide and Platinum Followed by MK-7684A vs Atezolizumab in Combination with Etoposide and Platinum Followed by Atezolizumab for the First-Line Treatment of Participants with Extensive-Stage Small Cell Lung Cancer
    TUCH / Maria SilvonimeiMO43576/IMscin002A RANDOMIZED, MULTICENTER, OPEN-LABEL CROSS-OVER STUDY TO EVALUATE PARTICIPANT AND HEALTHCARE PROFESSIONAL REPORTED PREFERENCE FOR SUBCUTANEOUS ATEZOLIZUMAB COMPARED WITH INTRAVENOUS ATEZOLIZUMAB FORMULATION IN PARTICIPANTS WITH NONSMALL CELL LUNG CANCER
    OTHER
    TUCH / Kalle MattilaPD-1 HeartPredictive clinical, imaging and laboratory biomarkers of cardiac toxicity related to anti-programmed death (PD)-1 therapies
    TUCH / Panu JaakkolaMATINSA phase I/II open-label, three part, dose-finding and separate cohort expansion trial to assess the safety, tolerability and preliminary efficacy of repeated doses of CLEVER-1 antibody FP-1305 in subjects with advanced solid tumours
    TUCH / Erika AlanneFINPROVEThe Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs to determine the Efficacy in Treatment of Advanced Cancers with a Known Molecular Profile
    TUCH / Maria SundvallBIOURICADevelopment of a biosensor to detect urine-based cancer biomarkers
    PEDIATRIC
    TUCH / Päivi LähteenmäkiIntreALL 2010 HRInternational Study for Treatment of High Risk Childhood Relapsed ALL 2010, A randomized Phase II Study Conducted by the Resistant Disease Committee of the International BFM Study Group
    TUCH / Päivi LähteenmäkiALL TogetherA Treatment study protocol of the ALLTogether Consortium
    for children and young adults (1-45 years of age) with newly diagnosed acute
    lymphoblastic leukaemia (ALL),
    TUCH / Päivi LähteenmäkiLBL 2018International cooperative treatment protocol for children and adolescents
    with lymphoblastic lymphoma
    TUCH / Päivi LähteenmäkiNHL 2013Treatment protocol of the NHL-BFM and the NOPHO study groups for mature
    aggressive B-cell lymphoma and leukemia in children and adolescents
    TUCH / Miia MokkaTEDDIRadiotherapy Delivery in Deep Inspiration for Pediatric Patients
    TUCH / Päivi LähteenmäkiINFORMINdividualized Therapy FOr Relapsed
    Malignancies in Childhood
    TUCH / Anu HuurrerEEcurInternational Randomised Controlled Trial of Chemotherapy for the Treatment of Recurrent and Primary Refractory Ewing Sarcoma
    TUCH / Minna KoskenvuoEvaluation of long-term Safety in Peadiatric With B-precursor Acute Lymphoblastic Leukemia (ALL) who Have Been Treated Either Bliunatumomab or Chemotherapy, Followed by Transplantation
    TUCH / Laura KorhonenPeCCaPSPersonal Crisis and Cancer Predisposition Syndromes.
    TUCH / Riikka Kuvaja and Päivi LähteenmäkiPACSShort and long-term consequences of pregnancy-associated cancer in women and their children.
    Read more about ongoing trials
    • Turun yliopiston lääketieteellisen tiedekunnan syöpään liittyvät tutkimushankkeet (in Finnish)
    • Turku Cancer Research Society
    • Join a cancer trial (for patients)

    Hospital Districts

    The Hospital District of Southwest Finland

    The Hospital District of Satakunta Region (in Finnish)

    Vaasa Hospital District

    • FICAN West
    • For patients
    • For professionals
    • For researchers
    • Contact
    • European Reference Networksin logoEuropean Reference Networks
    • Satakunnan sairaanhoitopiirin logoSatasairaala – satakunnan sairaanhoitopiiri
    • Varsinais-Suomen sairaanhoitopiirin logoVarsinais-Suomen sairaanhoitopiiri
    • Vaasan sairaanhoitopiirin logoVaasan sairaanhoitopiiri
    • Turun yliopiston logoTurun yliopisto
    • Turun yliopistollisen keskussairaalan logoTYKS – Turun yliopistollinen keskussairaala
    • Organisation European Cancer InstituteOECI – Organisation European Cancer Institute
    Scroll to top